TILs

July 5, 2016July 5, 2016

Bladder Cancer Patients Might Receive Better Targeted Treatment with Cancer Genetics’ New Complementary Diagnostic Test

News

Immunotherapy treatment for certain bladder cancers may be prescribed specifically for individual patients with help from a new FDA approved complementary test by Cancer Genetics (GCI). VENTANA PD-L1 (SP142), used with the diagnostic immunohistochemistry (IHC) test ... Read more

April 22, 2016April 22, 2016

Immunovaccine’s DepoVax-based Cancer Vaccine May Improve Checkpoint Inhibitors

News

Immunovaccine Inc. recently presented new preclinical data at the American Association for Cancer Research Annual Meeting 2016 revealing that a combination immunotherapy using a DepoVax-based vaccine could enhance the anti-tumoral effects of PD-1 ... Read more

February 29, 2016February 29, 2016

Immunotherapy Potential of Diabetes Drug, Metformin, Explained and Strongly Supported in Study

News

Japanese research into the anti-cancer effects of metformin, a prescribed drug for type 2 diabetes, indicates that the drug’s mechanism is immune-mediated and that it works by preventing the apoptosis and exhaustion of key ... Read more

March 3, 2015March 3, 2015

Novel Test Links Immune Hotspots to Improved Breast Cancer Prognosis

News

A recent study established an automated histological image processing technique to quantify spatial heterogeneity in the distribution patterns of tumor-infiltrating lymphocytes (TILs) in breast cancer. The study entitled “Beyond immune density: ... Read more

February 6, 2015

Novel Assay To Identify Effective Immune Therapies In Lung Cancer Patients

News

In a recent study titled “Objective Measurement and Clinical Significance of TILs in Non–Small Cell Lung Cancer” and published in the Journal of the National Cancer Institute, a research team from ... Read more

October 14, 2014October 14, 2014

Study Optimizes Platform to Expand Tumor Infiltrating Lymphocytes (TILs) For Melanoma Treatment

News

In a recent study titled “Activation and Propagation of Tumor-infiltrating Lymphocytes on Clinical-grade Designer Artificial Antigen-presenting Cells for Adoptive Immunotherapy of Melanoma” published in the Journal of Immunotherapy, a team ... Read more

October 9, 2014October 9, 2014

Tumour Infiltrating Lymphocytes for Cancer Treatment and Prognosis

News

During the European Society for Medical Oncology (ESMO) congress 2014, Madrid, different studies highlighted the importance of tumor infiltrating lymphocytes (TILs) in cancer prognostic and treatment. The tumor microenvironment is ... Read more

August 26, 2014August 26, 2014

PD-L1 (SP142) Antibody Developed By Spring Bioscience To Be Studied As Cancer Immunotherapy

News

A new PD-L1 (SP142) rabbit monoclonal immunohistochemistry (IHC) antibody developed as a part of Roche/Genentech’s anti-PD-L1 (MPDL3280A) immunotherapy program has been released commercially by Spring Bioscience (Spring), a member of ... Read more

August 14, 2014August 14, 2014

Peregrine Pharmaceuticals Reveals Preclinical Data on PS-Targeting Antibodies, Anti-PD-1 Antibodies

News

Peregrine Pharmaceuticals Inc. will announce its preclinical data validating the potent immune-stimulatory mechanism of its phosphatidylserine (PS)-targeting immuno-oncology platform at the 9th Annual Immunotherapies and Vaccine Summit being held August 11-14, 2014 in Boston, ... Read more